Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Teitelbaum

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Canada Diseases Weekly Report = Rapport Hebdomadaire Des Maladies Au Canada|September 1, 1990
Domoic acid toxicity. Panel discussion: treatmentJ W Olney, J Teitelbaum, C Pinsky, et al.
Biochimica Et Biophysica Acta|January 12, 1979
Purification and some properties of liver and brain beta-N-acetyl-hexosaminidase SM Potier, J Teitelbaum, S B Melancon, et al.
Proceedings of the Western Pharmacology Society|January 1, 1981
A HPLC radiometric assay to quantitate flunisolide metabolites in body fluidsN I Chu, P J Teitelbaum, M D Chaplin
Neurocritical Care|February 12, 2014
The ketamine effect on ICP in traumatic brain injuryF A Zeiler, J Teitelbaum, M West, et al.
Issue Brief (George Washington University. Center for Health Services Research and Policy)|November 12, 2002
An overview of Medicaid managed care litigationS Rosenbaum, J Teitelbaum, C Kirby, et al.
Canada Diseases Weekly Report = Rapport Hebdomadaire Des Maladies Au Canada|September 1, 1990
Domoic acid toxicity. Panel discussion: definition of the syndromeT M Perl, J Teitelbaum, J Hockin, et al.
Neurocritical Care|February 13, 2014
NMDA antagonists for refractory seizuresF A Zeiler, J Teitelbaum, L M Gillman, et al.
Neurocritical Care|April 10, 2014
THAM for control of ICPF A Zeiler, J Teitelbaum, L M Gillman, et al.
Case Reports in Critical Care|December 30, 2014
Early Implementation of THAM for ICP Control: Therapeutic Hypothermia Avoidance and Reduction in Hypertonics/HyperosmoticsF A Zeiler, L M Gillman, J Teitelbaum, et al.
Issue Brief (George Washington University. Center for Health Services Research and Policy)|November 13, 2002
An evaluation of agreements between managed care organizations and community-based mental illness and addiction disorder treatment and prevention providersS Rosenbaum, J Teitelbaum, D R Mauery, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Canada Diseases Weekly Report = Rapport Hebdomadaire Des Maladies Au Canada|September 1, 1990
Domoic acid toxicity. Panel discussion: treatmentJ W Olney, J Teitelbaum, C Pinsky, et al.
Biochimica Et Biophysica Acta|January 12, 1979
Purification and some properties of liver and brain beta-N-acetyl-hexosaminidase SM Potier, J Teitelbaum, S B Melancon, et al.
Proceedings of the Western Pharmacology Society|January 1, 1981
A HPLC radiometric assay to quantitate flunisolide metabolites in body fluidsN I Chu, P J Teitelbaum, M D Chaplin
Neurocritical Care|February 12, 2014
The ketamine effect on ICP in traumatic brain injuryF A Zeiler, J Teitelbaum, M West, et al.
Issue Brief (George Washington University. Center for Health Services Research and Policy)|November 12, 2002
An overview of Medicaid managed care litigationS Rosenbaum, J Teitelbaum, C Kirby, et al.
Canada Diseases Weekly Report = Rapport Hebdomadaire Des Maladies Au Canada|September 1, 1990
Domoic acid toxicity. Panel discussion: definition of the syndromeT M Perl, J Teitelbaum, J Hockin, et al.
Neurocritical Care|February 13, 2014
NMDA antagonists for refractory seizuresF A Zeiler, J Teitelbaum, L M Gillman, et al.
Neurocritical Care|April 10, 2014
THAM for control of ICPF A Zeiler, J Teitelbaum, L M Gillman, et al.
Case Reports in Critical Care|December 30, 2014
Early Implementation of THAM for ICP Control: Therapeutic Hypothermia Avoidance and Reduction in Hypertonics/HyperosmoticsF A Zeiler, L M Gillman, J Teitelbaum, et al.
Issue Brief (George Washington University. Center for Health Services Research and Policy)|November 13, 2002
An evaluation of agreements between managed care organizations and community-based mental illness and addiction disorder treatment and prevention providersS Rosenbaum, J Teitelbaum, D R Mauery, et al.
Pageof 10